Year: 2024

Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma. Presented data supporting RTNova (CLD-400), the company’s systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Diego, California. Raised $2 million in a registered direct offering and concurrent private placement.SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September 30, 2024, and reviewed recent...

MARKHAM, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three and nine months ended September 30, 2024, and the Company announced that it is exercising its option to redeem all of the outstanding $126.5 million principal amount of 2018-1 5.00% convertible unsecured subordinated debentures (TSX: EXE.DB.C) (the “2025 Debentures”). Third Quarter 2024 HighlightsAdjusted EBITDA(1) excluding out-of-period items increased by $13.5 million or 64.9% to $34.3 million, largely driven by rate increases in long-term care (“LTC”) and home health care and volume growth in home health care and managed services. Home health care average daily volume (“ADV”) grew to 30,181, up 10.2% from Q3 2023. SGP third-party and joint venture serviced beds increased 11.4%...

FORT WORTH, Texas, Nov. 12, 2024 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the third fiscal quarter of 2024. Highlights from Third Quarter 2024:Revenues were $17.4 million, down 1.1% from 2023 Operating loss of $0.3 million Net loss of $0.1 million, down from net income of $0.6 million in 2023 Gross margins of 57.8%, down from 62.4% in 2023 Operating expenses $10.3 million, up 2.3% from 2023 Adjusted EBITDA* of $0.2 million Ended quarter with $10.1 million of cash and cash equivalentsTandy Leather Factory’s third quarter sales were $17.4 million in 2024, down from $17.5 million in 2023. Third quarter 2024 gross profit was $10.0 million, down from $10.9 million in 2023. Third quarter saw an operating loss of $0.3 million, down from operating income of $0.9...

HONG KONG, Nov. 12, 2024 (GLOBE NEWSWIRE) — Oriental Culture Holding LTD. (“OCG” or the “Company”) (NASDAQ: OCG), a leading online provider of collectibles and artwork e-commerce services, today announced its unaudited financial results for the six months ended June 30, 2024. First Half Year of 2024 Financial HighlightsTotal revenues were approximately $0.4 million for the six months ended June 30, 2024, compared with the total revenues of approximately $0.8 million for the six months ended June 30, 2023. Gross profit was approximately $0.3 million for the six months ended June 30, 2024, compared with approximately gross profit of $0.6 million for the six months ended June 30, 2023. Gross margin was 65.8% for the six months ended June 30, 2024, compared with a gross margin of 76.0% for the six months ended June 30, 2023. Loss...

VANCOUVER, British Columbia, Nov. 12, 2024 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning”, the “Company”, “we”, “our” or “us”) reported third quarter 2024 results today. All monetary amounts are in Canadian dollars unless otherwise stated. HIGHLIGHTSAll comparisons are to Q3 2023 results unless indicated otherwise.Q3 2024 free cash flow (3) of $346 million, up from Q3 2023 driven by invested capital velocity improvement. In the last twelve months, we have generated cumulative free cash flow of $746 million. Q3 2024 revenue of $2.8 billion and net revenue (2) of $2.5 billion were up 5% and 4%, respectively. New equipment revenue was up 7% and product support revenue was up 2%. Q3 2024 EBIT (1) was $170 million and EBIT as a percentage of net revenue (2) was 6.7%. Excluding an estimated loss for receivables...

Record total revenue of $43.8 million, up 8% year-over-yearQ3 annualized recurring revenue crosses $100 million milestone, up 11% year-over-yearNet loss improved 14% year-over-year; Non-GAAP net loss improved 80% year-over-yearTotal subscribers grew to 1.1 million, up 25% year-over-yearSquare feet under management reached 47.3 billion, up 34% from prior yearSUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Matterport, Inc. (Nasdaq: MTTR) (“Matterport” or the “Company”), the leading spatial data company driving the digital transformation of the built world, today announced financial results for the quarter ended September 30, 2024. “I’m pleased to share our third-quarter 2024 results, highlighting our continued success driving efficient growth,” said RJ Pittman, Chairman and CEO of Matterport. “Total square feet...

Transition of Heavy-Duty OEM assets into Cespira, where they generated revenue of $16.2 million outweighs quarter-over-quarter revenue decline of $11.2 million VANCOUVER, British Columbia, Nov. 12, 2024 (GLOBE NEWSWIRE) — Westport Fuel Systems Inc. (“Westport“) (TSX:WPRT / Nasdaq:WPRT), a leading supplier of advanced alternative fuel systems and components for the global transportation industry, reported financial results for the third quarter ended September 30, 2024, and provided an update on operations. All figures are in U.S. dollars unless otherwise stated. “Westport delivered solid results in the third quarter of 2024. Although revenue was down, this decrease was more than outweighed by the revenue earned at Cespira and we delivered significant improvement in Adjusted EBITDA. We continue to execute against our three...

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the Prescription Drug User Fee Act (“PDUFA”) goal date set for next month, we await the decision by the U.S. Food and Drug Administration (“FDA”) on our Biologics License Application (“BLA”) resubmission for cosibelimab, our anti-programmed death ligand-1 (“PD-L1”) antibody,” said James Oliviero, President and Chief Executive Officer of Checkpoint. “The $9.2 million in cash proceeds received this month from the exercise of existing warrants...

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company specializing in the management, recovery, and conversion of biogas into renewable natural gas (“RNG”), today announced financial results for the third quarter ended September 30, 2024. Third Quarter Financial Highlights:RINs Sold of 15.8 million, increased 14.5% compared to the third quarter of 2023Revenues of $65.9 million, increased 18.4% compared to the third quarter of 2023Net Income of $17.0 million, increased 31.8% compared to the third quarter of 2023Non-GAAP Adjusted EBITDA of $29.4 million, increased 31.3% compared to the third quarter of 2023RNG production of 1.4 million MMBtu, flat compared to the third quarter of 2023Our production was significantly impacted by...

DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) — DallasNews Corporation (Nasdaq: DALN) (the “Company”) today reported a third quarter 2024 net loss of $3.9 million, or $(0.73) per share, and an operating loss of $4.1 million. In the third quarter of 2023, the Company reported a net loss of $1.4 million, or $(0.26) per share, and an operating loss of $1.6 million. The third quarter 2024 net loss includes severance expense of $3.0 million, primarily due to the Company’s anticipated headcount reductions related to the previously announced transition to a smaller printing facility. For the third quarter of 2024, on a non-GAAP basis, DallasNews reported operating loss adjusted for certain items (“adjusted operating loss”) of $0.7 million, an improvement of $0.2 million or 18.5 percent when compared to an adjusted operating loss of $0.9 million...